DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 76 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactOrders & Deals

Anupam Rasayan acquires 50.07% stake in Bliss GVS Pharma For ₹1,600 Crore

Trade Brains 1 hr ago·29 Sept 2026, 6:55 am

Anupam Rasayan has acquired a majority stake of 50.07% in Bliss GVS Pharma for ₹1,600 crore. This strategic move allows Anupam Rasayan to gain control over Bliss GVS, a company known for its expertise in drug formulation and manufacturing.

This acquisition is significant for investors as it signals Anupam Rasayan's intent to expand its portfolio and strengthen its market position in the pharmaceutical sector. The deal is expected to create synergies and enhance the combined entity's capabilities in drug development and production.

Investors should watch for updates on the integration plans and how this strategic partnership will impact the financial performance of both companies in the coming quarters.